GE HealthCare Q3 FY2026: sales up 7.2%, EPS up 39.1%, guidance raised
GE HealthCare beat on both lines and lifted full-year guidance: revenue rose 7.2% to $5.51 billion and adjusted EPS of $1.34 came in $0.11 above the $1.23 consensus. Read the quarter in three steps. Growth was broad across all three segments, margins expanded as volume and price outran inflation, and free cash flow jumped 64.2%. The one blemish is a $394 million inventory build.
1 · Expected vs. Actual
Free preview belowDiluted EPS of $1.36 rose 39.1% from $0.98, while adjusted EPS of $1.34 rose 25.1% from $1.07 and beat the $1.23 consensus by 9.1%. The gap between the two lines is mostly acquisition-related amortization and restructuring, which is normal for this company. Be aware that adjusted EPS includes a $0.02 benefit from tariff refunds, so the clean beat is slightly smaller.
Revenue of $5.51 billion rose 7.2% from $5.14 billion, but organic growth was 6.2%, so roughly a point came from currency and the $68 million of acquired revenue. All three segments grew: Advanced Imaging Solutions 6.1%, Pharmaceutical Diagnostics 13.0% and Patient Care Solutions 8.5%. Orders grew 4.0% organically with a book-to-bill of 1.03 times, so demand kept pace with the sales booked.
Log in to read 35 analyses a week for free
Create a free account to read 35 full earnings analyses each week — all five steps: expected vs. actual, guidance tracker, money flow, balance sheet and risks. Members get unlimited access.
Figures on this page come from the company's original SEC filings. The analysis is generated automatically and checked against validation rules, but may still contain errors or omissions. Not investment advice. · Generated 2026-11-03
Answers are based on the earnings release and the analysis above. Free accounts get 3 questions a week; members get 30 a day.